Who Owns Exelon?
Exelon is a brand name owned by Novartis AG, a publicly traded Swiss multinational pharmaceutical company (SIX: NOVN, NASDAQ: NVS). Novartis developed rivastigmine internally and received FDA approval in 1997. The brand is marketed globally by Novartis and its generics division Sandoz, with generic rivastigmine now widely available. Novartis is headquartered in Basel, Switzerland.
Parent Company
Novartis
Founded
1997
Status
Publicly Traded
Headquarters
Basel, Switzerland
Who Owns Exelon?
- Parent Company: Novartis
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: SIX: NOVN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Exelon | Novartis | Wholly owned |
History of Exelon
- Founded: 1997
- Founders: Novartis (internal development)
Rivastigmine, the active compound marketed as Exelon, was developed by Sandoz Pharma Ltd. in Basel, Switzerland, as part of a research program targeting the cholinergic deficit hypothesis of Alzheimer's disease. The hypothesis, which gained scientific consensus during the 1970s and 1980s, proposed that the cognitive decline characteristic of Alzheimer's disease was partly attributable to the loss of cholinergic neurons in the basal forebrain, resulting in reduced levels of the neurotransmitter acetylcholine in the cerebral cortex and hippocampus. Researchers at Sandoz identified rivastigmine as a selective inhibitor of acetylcholinesterase and butyrylcholinesterase, the enzymes responsible for breaking down acetylcholine, thereby increasing the availability of the neurotransmitter at synaptic junctions.
The development of rivastigmine proceeded through the 1980s and into the early 1990s, a period that coincided with the 1996 merger of Ciba-Geigy and Sandoz to form Novartis AG. The newly formed Novartis inherited the rivastigmine development program and advanced it through Phase III clinical trials. The pivotal trials demonstrated statistically significant improvements in cognitive function and activities of daily living in patients with mild-to-moderate Alzheimer's disease compared to placebo, supporting the drug's regulatory submissions.
The U.S. Food and Drug Administration approved Exelon (rivastigmine) capsules on April 21, 1997, for the treatment of mild-to-moderate dementia associated with Alzheimer's disease. This approval made rivastigmine one of the first cholinesterase inhibitors to receive regulatory clearance in the United States, alongside donepezil (Aricept, approved 1996) and tacrine (Cognex, approved 1993 but later withdrawn due to hepatotoxicity concerns). The European Medicines Agency granted approval in the same period, enabling Novartis to launch Exelon across major global markets.
A significant advancement came in 2000 when Novartis received approval for Exelon oral solution, which improved dosing flexibility for patients who had difficulty swallowing capsules, a common challenge in the elderly Alzheimer's population. The drug's label was subsequently expanded in 2006 to include the treatment of dementia associated with Parkinson's disease, broadening the eligible patient population and reinforcing Exelon's position in the neurological dementia treatment category.
The most commercially significant formulation development was the Exelon Patch, a transdermal rivastigmine delivery system approved by the FDA in July 2007. The patch offered several clinical advantages over oral formulations: more consistent plasma drug concentrations, reduced gastrointestinal side effects that had been a limiting factor with oral rivastigmine, and simplified once-daily administration that improved patient adherence. Clinical trials demonstrated that the 9.5 mg/24h patch provided efficacy comparable to the highest recommended oral dose with significantly better gastrointestinal tolerability. In 2013, the FDA approved a higher-dose 13.3 mg/24h patch for patients with severe Alzheimer's disease, making Exelon Patch the first and only transdermal therapy approved across all stages of Alzheimer's disease.
Generic rivastigmine capsules and oral solution became available in the United States following patent expiry, with multiple manufacturers receiving FDA approval. Sandoz, Novartis's own generics division, also markets generic rivastigmine, effectively competing with the branded Exelon in the oral formulation segment. The Exelon Patch retained longer patent protection, and Novartis has focused its branded marketing efforts on the transdermal formulation, where clinical differentiation and brand recognition continue to support commercial performance despite the availability of generic rivastigmine patches from competing manufacturers.
About Novartis
What does Novartis own?
Novartis owns a portfolio of innovative prescription medicines across oncology, immunology, cardiovascular, neuroscience, and ophthalmology. Key products include Cosentyx (inflammatory diseases), Entresto (heart failure), Kisqali (breast cancer), Kesimpta (multiple sclerosis), Leqvio (cholesterol), Zolgensma (gene therapy for spinal muscular atrophy), and Kymriah (CAR-T cell therapy). Novartis spun off its Sandoz generics division in 2023 and its Alcon eye care division in 2019.
Is Novartis publicly traded?
Yes, Novartis AG is listed on the SIX Swiss Exchange under ticker NOVN and on NASDAQ under ticker NVS (as American Depositary Receipts). The company has a broad institutional and retail shareholder base with no single controlling shareholder. Major institutional shareholders include Vanguard Group and BlackRock.
Who founded Novartis?
Novartis was formed in 1996 through the merger of Ciba-Geigy and Sandoz, two of Switzerland's oldest pharmaceutical companies. Ciba-Geigy itself was formed through the 1970 merger of Ciba and Geigy, both founded in Basel in the 19th century. Sandoz was founded in 1886 in Basel. The 1996 merger was one of the largest corporate mergers in history at the time, valued at approximately $63 billion.
Where is Novartis headquartered?
Novartis AG is headquartered in Basel, Switzerland. Basel has been the center of the Swiss pharmaceutical industry for more than a century, and Novartis, Roche, and several other major pharmaceutical companies are headquartered in the city. Novartis operates manufacturing and research facilities in Switzerland, the United States, Germany, Spain, Italy, Japan, China, India, Singapore, and Brazil.
How many products does Novartis sell?
Novartis sells dozens of prescription medicines across multiple therapeutic areas. The company's growth portfolio is led by Cosentyx, Entresto, Kisqali, Kesimpta, Leqvio, Zolgensma, and Kymriah. Novartis has a pipeline of more than 150 projects in clinical development across its therapeutic focus areas. The company sells products in more than 140 countries worldwide.
Who owns Novartis?
Novartis AG is publicly traded on the SIX Swiss Exchange and NASDAQ with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. The Novartis Foundation for Employee Participation holds a significant stake. Major institutional shareholders include Vanguard Group and BlackRock. Vas Narasimhan serves as CEO and Joerg Reinhardt chairs the board.
- Founded: 1996
- Headquarters: Basel, Switzerland
- Company Type: Publicly Traded
- Stock: SIX: NOVN
- Revenue: approximately $50.3 billion (FY2024)
- Employees: Approximately 100,000
Where Is Exelon Made / Based?
- Headquarters: Basel, Switzerland
- Manufacturing / Operations: Switzerland, Germany, United States, Ireland
Exelon Sustainability & Ethics
Exelon's sustainability and ethical practices focus on sustainable pharmaceutical manufacturing, environmental responsibility, and ethical clinical trials within Novartis' comprehensive sustainability framework. The brand is committed to reducing its environmental footprint through sustainable manufacturing processes, responsible sourcing, and ethical research practices while maintaining the quality and safety expected of a prescription medication for neurological conditions.
Sustainable Manufacturing and Environmental Compliance: Exelon emphasizes sustainable manufacturing practices across its production facilities, including energy-efficient processes, waste reduction initiatives, and carbon footprint measurement. The brand focuses on reducing emissions through manufacturing optimization and supporting Novartis's broader environmental goals while maintaining the high standards expected of pharmaceutical production.
Ethical Pharmaceutical Practices: Exelon maintains ethical pharmaceutical practices across all research, development, and manufacturing processes, including fair labor practices, safe working conditions, and transparent supply chain management. The brand works closely with manufacturing partners to ensure ethical standards are maintained throughout the production process.
Clinical Trial Ethics: Exelon prioritizes ethical clinical trial practices, including patient safety, informed consent, and transparent reporting. The brand supports ethical research methodologies and patient protection while maintaining the scientific rigor expected of clinical pharmaceutical development.
Healthcare Accessibility: Exelon emphasizes healthcare accessibility through responsible pricing strategies, patient assistance programs, and global availability initiatives. The brand supports healthcare access initiatives while maintaining the quality standards expected of prescription medications.
Community Engagement: Exelon supports local communities through educational programs, healthcare initiatives, and partnerships with patient organizations. The brand maintains its commitment to community development while operating as a significant contributor to healthcare awareness and patient education.
Awards & Recognition
Exelon has received recognition within the pharmaceutical industry for its innovative approach to Alzheimer's disease treatment, clinical research excellence, and patient care contributions, establishing itself as a respected brand in the neurology pharmaceutical market.
Innovation Awards: Exelon's development of rivastigmine as the first FDA-approved cholinesterase inhibitor for Alzheimer's disease has received recognition from pharmaceutical organizations and medical associations. The brand's innovative approach to symptomatic treatment has been acknowledged as advancing Alzheimer's disease management and patient care.
Clinical Research Recognition: Exelon's clinical trials and research studies have received recognition from medical research organizations and neurology associations. The brand's commitment to rigorous clinical methodology and scientific rigor has been acknowledged as contributing to pharmaceutical research excellence.
Patient Care Awards: Exelon's patient support programs and educational initiatives have received recognition from patient organizations and healthcare associations. The brand's focus on patient education and support has been acknowledged as contributing to patient care quality and disease management.
Regulatory Recognition: Exelon's regulatory approval process and compliance achievements have received recognition from regulatory bodies and pharmaceutical authorities. The brand's successful FDA approval and subsequent regulatory milestones have been acknowledged as demonstrating regulatory excellence.
Exelon Recalls & Controversies
Exelon has maintained a strong safety record but has faced some challenges related to efficacy limitations, market competition, and healthcare industry transitions that are typical in the pharmaceutical sector.
Efficacy Limitations: While Exelon maintains comprehensive safety protocols, the pharmaceutical industry has faced occasional efficacy challenges that have affected confidence in medications broadly. Exelon has addressed these challenges through enhanced clinical research and clear communication with healthcare providers, prioritizing patient safety and therapeutic effectiveness.
Market Competition Challenges: Exelon faces intense competition in the neurology pharmaceutical market from other cholinesterase inhibitors and emerging disease-modifying therapies. This competition has created pressure on pricing, market positioning, and therapeutic strategy, requiring continuous adaptation to maintain market relevance.
Generic Competition: The brand has faced challenges related to generic competition following patent expiry, particularly regarding pricing pressure and market share erosion. These challenges have required strategic adaptation to changing market dynamics and competitive landscapes.
Regulatory and Compliance Issues: Exelon has faced challenges related to regulatory compliance, particularly regarding FDA requirements and international regulatory standards. These challenges have required continuous improvement in compliance processes and regulatory adherence.
Healthcare Industry Transition: The brand has faced challenges related to healthcare industry transitions, particularly regarding the shift toward disease-modifying therapies and changing treatment paradigms. These transitions have required strategic adaptation to evolving medical approaches and treatment standards.
Brands Owned by Novartis
- Afinitor - Prescription oncology medicine (everolimus) used to treat certain cancers and tu...
- Alcon - Independent publicly traded global eye care company headquartered in Geneva, Swi...
- Cosentyx - Prescription biologic medication for treating autoimmune diseases including psor...
- Gilenya - Prescription immunosuppressant medication for treating relapsing-remitting multi...
- Lamisil - Over-the-counter antifungal medication for treating fungal infections including ...
- Lucentis - Prescription biologic medication for treating age-related macular degeneration a...
- Otrivin - Over-the-counter nasal decongestant spray for relieving nasal congestion from co...
- Sandoz - Independent global leader in generic and biosimilar pharmaceuticals, spun off fr...
- Tasigna - Prescription oncology medication for treating chronic myeloid leukemia, owned by...
- Theraflu - Over-the-counter cold and flu relief medication combining multiple active ingred...
- Voltaren - Over-the-counter anti-inflammatory pain relief brand containing diclofenac, owne...
Exelon Ownership: Pros & Cons
Advantages
- +Novartis's global regulatory infrastructure enables Exelon to maintain marketing authorizations across more than 100 countries, providing commercial reach that independent pharmaceutical brands rarely achieve
- +The Exelon Patch formulation retains clinical differentiation through its transdermal delivery mechanism, which offers documented tolerability advantages over oral rivastigmine and supports continued branded prescribing despite generic competition
- +Decades of post-marketing safety data and physician familiarity create institutional inertia that supports continued prescribing in clinical settings where established treatments are preferred over newer alternatives
- +Novartis's pharmacovigilance and medical affairs infrastructure ensures ongoing label maintenance, physician education, and regulatory compliance without the resource constraints that would affect a smaller independent pharmaceutical company
Considerations
- -Generic rivastigmine from multiple manufacturers has substantially eroded branded Exelon's market share in oral formulations, limiting revenue growth potential in the oral segment to markets with limited generic penetration
- -The approval of disease-modifying Alzheimer's therapies (lecanemab, donanemab) has shifted clinical and investor attention away from symptomatic treatments, potentially reducing the long-term commercial relevance of the cholinesterase inhibitor class
- -Exelon addresses symptoms rather than the underlying pathology of Alzheimer's disease, a limitation that has become more prominent as disease-modifying therapies demonstrate the clinical feasibility of slowing disease progression
- -Reimbursement pressures in major markets, particularly in the United States under Medicare drug price negotiation provisions, create ongoing pricing headwinds for established branded pharmaceuticals with available generic alternatives
Frequently Asked Questions About Exelon
Sources & Further Reading
Where to Buy
Disclosure: We may earn commission from purchases
Exelon on AmazonCompetitors to Exelon
No direct competitors found in the same category. This could be because Exelonoperates in a unique market segment or we're still building our competitor database.
Novartis Stock Information
Jobs at Novartis
Latest News About Exelon
Related Articles About Exelon
View more articles
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Monthly IPO Roundup: July 2026 — June's Biggest Listings
June 2026 was the most historic IPO month in market history: SpaceX priced at $135 per share on June 12, raising $75 billion in the largest IPO ever. Quantinuum raised $1.68B, INNIO priced a $2.8B deal, and Bending Spoons filed for a $20B Nasdaq listing. Full recap.
Monthly M&A Roundup: June 2026 Brand Ownership Changes
June 2026's biggest brand ownership moves: Berkshire Hathaway agreed to buy Taylor Morrison for $6.8B, GSK struck a $10.6B deal for Nuvalent, CRH acquired Arcosa for $8.5B, and Qualcomm agreed to buy AI startup Modular for $3.92B. Full breakdown of every major deal.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Acuvue
Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.